The FDA has approved Novartis’ Diovan HCT (valsartan/hydrochlorothiazide tablets) and Exforge (amlodipine/valsartan tablets) as first-line therapies for hypertension in patients likely to need ...

Latest Health Technology at CES 2021; Jury Awards Huge Verdict After Physician Fails to Diagnose Rare Disorder; Prepare for the End of Pandemic Telehealth Waivers ...

The Diovan HCT and Exforge first-line approvals were based on several clinical trials in approximately 2,000 and 3,500 patients, respectively, in which both products demonstrated efficacy and ...

Amlodipine, Valsartan and Hydrochlorothiazide(Exforge HCT) generic contains calcium channel blocker, angiotensin II receptor blocker, and thiazide diuretic, prescribed for high blood pressure.

The reductions in SBP/DBP with Exforge HCT® were 7.6/5.0 mm Hg greater than those with valsartan/HCTZ, 6.2/3.3 mm Hg greater than those with amlodipine/valsartan, and 8.2/5.3 mm Hg greater than ...

Exforge HCT ® (Amlodipine, Valsartan, Hydrochlorothiazide) Tablets, marketed by Novartis Pharmaceuticals, had annual sales of approximately $158 million in the United States, according to ...

Exforge is a combination of two blood pressure blockbusters: Diovan from Novartis (down $0.38 to $55.14, Charts), which totaled $4.2 billion in 2006 sales, and Pfizer's Norvasc.

Diovan HCT is currently indicated in the USA as a second-line treatment for hypertension, while Exforge got the green light from the FDA last year to treat patients with high blood pressure who had ...

Teva Pharmaceutical Industries Limited ( TEVA) has launched its generic version of Novartis' ( NVS) Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) tablets in the U.S. Exforge HCT is ...